An observational study in Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis and Ovarian Vein Thrombosis, sponsored by University of Malta. Completed at 24 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by University of Malta · Observational
Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.
46 studies on the registry are indexed under Intracranial Thrombosis; 15 are open to participants now.
This study's enrollment of 358 is above the median of 319 across 26 observational studies indexed under Intracranial Thrombosis.
Browse Intracranial Thrombosis studies →University of Malta is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All consecutive patients who fulfill the inclusion/exclusion criteria at the participating thrombosis centers will be eligible
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
Also known as: Apixaban, Dabigatran, Edoxaban, Rivaroxaban
Rationale for the use of the direct oral anticoagulants
Possible reasons for choosing one of the direct oral anticoagulant (multiple choice question)
Time frame: Baseline
Rate of major bleeding events
Time frame: 12 months
Rate of vascular events
Time frame: 12 months
Ran from Oct 2019 to primary completion in Dec 2024, 62 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Malta